Kyorin Pharmaceutical, a subsidiary of Kyorin Holdings, Inc. and Sumitomo Pharma, in Japan, have entered into a license agreement for development, manufacturing, and commercialisation of a therapeutic agent for overactive bladder (OAB) called Vibegron as international nonproprietary name (INN), in Taiwan, Hong Kong, Singapore, Indonesia, and Vietnam.

Based on the agreement, Kyorin will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialise the compound in these five countries and regions. Kyorin will receive an upfront payment and is eligible to receive development and sales milestone payments from Sumitomo Pharma.

Following the launch of the compound, Kyorin is eligible to receive royalties based on net sales of the compound by Sumitomo Pharma. The compound is a once-daily oral selective β3-adrenergic receptor agonist. It acts selectively on the bladder's β3-adrenergic receptor, relaxes the bladder, and enhances the urine collection and consequently improves the symptoms of urgency, urinary frequency, and urge urinary incontinence associated with OAB.

Sumitomo Pharma will deliver the compound to patients who need it and will work to maximise profits in East and Southeast Asia, which Sumitomo Pharma is focusing on as a growth market for pharmaceutical products.